# Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response

> **NCT03609099** · PHASE4 · UNKNOWN · sponsor: **David Garcia Cinca** · enrollment: 424 (estimated)

## Conditions studied

- Community-acquired Pneumonia

## Interventions

- **DRUG:** Moxifloxacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03609099
- **Lead sponsor:** David Garcia Cinca
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-15
- **Primary completion:** 2020-11-15
- **Final completion:** 2021-05-15
- **Target enrollment:** 424 (ESTIMATED)
- **Last updated:** 2019-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03609099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03609099, "Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03609099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*